

## Online Appendix 1: Author Relationships with Industry and Other Entities (Comprehensive) — 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Sandeep R. Das (Co-Chair)	UT Southwestern Medical Center—Associate Professor of Medicine	Roche Diagnostics	None	None	None	None	None
Brendan M. Everett (Co-Chair)	Brigham and Women’s Hospital—Assistant Professor of Medicine	Abbott* FDA Roche Diagnostics	None	None	NHLBI † NIH/NIDDK (DSMB) Novartis †	Merck	None
Kim K. Birtcher	University of Houston College of Pharmacy— Clinical Professor	Jones & Bartlett Learning	None	None	None	Accreditation Council for Clinical Lipidology *	None
Jenifer M. Brown	Brigham and Women’s Hospital—Fellow in Cardiology	None	None	None	None	None	None
William T. Cefalu	American Diabetes Association—Chief Scientific, Medical and Mission Officer	None	None	None	None	None	None
James L. Januzzi	Massachusetts General Hospital—Professor of Medicine, Harvard Medical School	Abbott Critical Diagnostics † Philips Roche Diagnostics †	None	None	AbbVie (DSMB) † Amgen (DSMB) † Boehringer Ingelheim (DSMB) † Cleveland Heart Labs (DSMB) † Janssen Pharmaceuticals (DSMB) † Novartis † Prevensio † Siemens (DSMB) † Singulex †	None	None
Rita Rastogi Kalyani	Johns Hopkins University School of Medicine—Associate Professor of Medicine	None	None	None	None	None	None
Mikhail Kosiborod	Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City—Professor of Medicine	Amgen † AstraZeneca † Boehringer Ingelheim † Eisai Corporation GlaxoSmithKline	None	None	AstraZeneca † Boehringer Ingelheim †	None	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
		Glytec Intarcia † Janssen † Merck (Diabetes) † Novo Nordisk Sanofi † Novartis					
Melissa L. Magwire	Shawnee Mission Health— Endocrine Clinic Coordinator	None	Janssen Novo Nordisk † Sanofi-Aventis	None	None	None	None
Pamela B. Morris	Medical University of South Carolina—Director, Seinsheimer Cardiovascular Health Program; Co-Director, Women's Heart Care	Amgen Esperion Sanofi Regeneron	None	None	Amgen	Amgen‡ Esperion‡	None
Laurence S. Sperling	Emory Heart Disease Prevention Center— Professor of Medicine (Cardiology); Emory University—Director, Professor of Global Health, Hubert Department of Global Health, Rollins School of Public Health	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

\* No financial benefit.

† Significant relationship

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.